ASH Annual Meeting 2018
Advertisement
James Douketis, MD, McMaster University, Hamilton, Ontario, discusses the the PAUSE (the Perioperative Anticoagulant Use ...
During the 60th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego in December 2018, Peter ...
At the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, Aziz Nazha, MD of Cleveland Clinic ...
Mitchell Cairo, MD, Chief of Pediatric Hematology, Oncology and Stem Cell Transplantation; Director of the Children and ...
According to updated data from the phase II JULIET trial presented at the 2018 ASH Annual Meeting, the chimeric antigen ...
Jonathan U. Peled, MD, of Memorial Sloan Kettering Cancer Center discusses his study which looked at whether pre-HCT ...
Erica B. Esrick, MD, Hematologist at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center reported on her ...
Richard Thomas Maziarz, MD discusses the JULIET trial at the American Society of Hematology (ASH) Annual Meeting and ...
According to an update presented at the ASH annual meeting, tisagenlecleucel (Kymriah, Novartis) produced high response ...
Some patients receiving low-molecular-weight heparin (LMWH) such as enoxaparin benefit from routine laboratory ...
The most common reason children with sickle cell disease (SCD) are hospitalized is pain crisis, and hospitalizations ...
Chimeric antigen receptor (CAR) T-cell therapy has been shown to lead to high rates of complete response in relapsed ...
JCAR014 is a CD19-specific chimeric antigen receptor (CAR)-modified T-cell therapy developed by Juno Therapeutics. ...
Patients with cancer are at an increased risk of blood clots. Research presented at the 2018 ASH Annual Meeting showed ...
Luspatercept produced a clinically meaningful reduction of red blood cell (RBC) transfusions and was generally well ...
Michael Hallek, MD, of University Hospital, Cologne, Germany, delivered the Ham-Wasserman Lecture, titled “On the ...
Use of a Geriatric Assessment in Hematology (GAH) scale, used to classify patients according to frailty phenotype, has ...
The integration of mobile health technology for symptom management in acute pediatric blood and marrow transplant (BMT) ...
A proof-of-principle study has shown that cells edited to remove the genetic mechanisms for turning down the production ...
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.